Epioxa and iDose drive growth as payer access expands and milestones approach
Epioxa’s commercial launch is progressing as payer access expands and Photrexa has been sunset. iDose continues to grow with strong Medicare Advantage uptake, while the pipeline advances with multiple clinical milestones expected in the next 18 months.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.